Breast Cancers Today
Advertisement
Triplet therapy showed promising efficacy in PD-L1–negative TNBC in the ATRACTIB trial, with a 63% response rate.
Dr. Iyengar explains how metabolic health impacts cancer risk, treatment response, and outcomes across multiple tumor types.
Dr. Gradishar reviews PARP data, new combos, and tools to better select breast cancer patients for targeted treatment.
Dr Neil Iyengar joins Winship to lead breast oncology and survivorship, with a focus on metabolic health and cancer research.
HER2DX predicts outcomes in early HER2+ breast cancer, adding prognostic value beyond standard clinical-pathologic factors.
Dr. Sara Tolaney explores how DESTINY-Breast09 may reshape first-line treatment in HER2+ metastatic breast cancer.
Dr. Mark Robson discusses PARP inhibitors in TNBC, including mechanisms, combos, biomarkers, and treatment sequencing.
ChatGPT shows limited accuracy and consistency in breast cancer care, highlighting the need for expert clinical judgment.
Dr. Maryam Lustberg discusses real-world T-DXd use, biomarkers, and resistance in metastatic breast cancer care.
AI-enhanced HER2 scoring improves accuracy and may expand patient access to HER2-targeted therapies in breast cancer care.
Dr. Kelly McCann reviews sequencing and emerging therapies in HR-positive, HER2-negative metastatic breast cancer.
Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management.
Dr. Kelly McCann discusses evolving treatment sequencing strategies in metastatic triple-negative breast cancer.
Top research highlights from ESMO Breast Cancer 2025 showcase advances in treatment and care for patients with breast cancer.
Dr. David Waterhouse shares how clinical trials can be decentralized to better serve patients in community settings.
AI-assisted platform boosts accuracy in identifying HER2-low breast cancer, improving access to targeted therapies.
Cross-resistance data raise questions about sequencing ADCs in mBC; Dr. Lustberg discusses real-world outcomes and next steps
FDA authorizes CLAIRITY BREAST, the first AI tool to predict 5-year breast cancer risk from screening mammograms.
OncoPRO is advancing ePRO use in oncology through integration tips, EOM alignment, and improved patient outcomes.
ASCO 2025 study reveals gaps in fertility counseling and awareness among patients with cancer who are of reproductive age.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.